Francisco J. Esteva, MD, PhD
Although 6 months of adjuvant trastuzumab (Herceptin) demonstrated noninferiority to the standard 12 months in the phase III PERSEPHONE trial, Francisco J. Esteva, MD, PhD, said that it is unlikely to instantly shift the standard in the context of other clinical trials that have failed to demonstrate the same outcome.
State of the Science Summit™ on Breast Cancer, Esteva, medical oncologist, New York University’s Perlmutter Cancer Center, discussed recent advances and clinical findings with HER2-targeted therapies across the neoadjuvant, adjuvant, and metastatic settings.
OncLive: What are the improvements and advances in HER2-targeted therapy?
: There are some important data in the adjuvant setting for trastuzumab. [In my presentation], I also touched on some of the new therapies that are being explored in the metastatic setting.
... to read the full story